Incyte Shares Lifted by CMS Settlement and Analyst Upgrade
Incyte Corporation saw its stock gain in pre-market trading after the company settled a classification dispute with the Centers for Medicare & Medicaid Services regarding Opzelura (ruxolitinib) cream and disclosed an expected one-time, non-cash accounting benefit of about $246 million in the quarter ending June 30, 2026. The move came alongside…